vTv Therapeutics Receives FDA's Orphan Drug Designation For HPPD To Treat Sickle Cell Disease

vTv Therapeutics Inc. (NASDAQ: VTVT) has received Orphan Drug Designation from the U.S. FDA for HPPD, its first-in-class oral Nrf2/Bach1 modulator, which is being developed as a treatment for sickle cell disease. This designation is significant for the company's ongoing efforts in advancing its therapeutic pipeline.